HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Pharmeyes Cayman Holding / Equity Capital Markets

<ul>
<li>The financial data of Pharmeyes presents a contradictory situation where "stability" and "stagflation" coexist, as this "slow-growth industry" is hard to support the market's expectations for high growth of Pharmeyes.</li>
<li>Although its pioneering channel DDI solution has first-mover advantage, due to accelerating technological iteration, Pharmeyes needs to continuously prove its data platform can cope with the impact of emerging technologies.</li>
<li>Valuation would be lower than Medlive due to lower growth rate and profit margin. P/S of 3-4.5x could be a relatively conservative estimate, reflecting its growth concerns and risk profile</li>
</ul>


The financial data of Pharmeyes presents a contradictory situation where "stability" and "stagflation" coexist, as this "slow-growth industry" is hard to support the market's expectations for high growth of Pharmeyes.
Although its pioneering channel DDI solution has first-mover advantage, due to accelerating technological iteration, Pharmeyes needs to continuously prove its data platform can cope with the impact of emerging technologies.
Valuation would be lower than Medlive due to lower growth rate and profit margin. P/S of 3-4.5x could be a relatively conservative estimate, reflecting its growth concerns and risk profile


Pre-IPO Pharmeyes Cayman Holding - The Technical Barriers Are Not High

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pharmeyes Cayman Holding (PCH HK)

Pre-IPO Pharmeyes Cayman Holding - The Technical Barriers Are Not High

Pharmeyes faces challenges in a slow-growth industry, needing to prove its data platform can keep up with emerging technologies to support market...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pre-IPO Pharmeyes Cayman Holding - The Technical Barriers Are Not High

​Pharmeyes faces challenges in a slow-growth industry, needing to prove its data platform can keep up with emerging technologies to support market...

Xinyao (Criss) Wang

Pharmeyes faces challenges in a slow-growth industry, needing to prove its data platform can keep up with emerging technologies to support market...